Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

HIGHLIGHTS

• who: Refractory chronic gout et al. from the (UNIVERSITY) have published the Article: Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials, in the Journal: (JOURNAL)
• what: One strength of the present analysis is the utilization of prospectively collected data derived from randomized clinical trials that featured a placebo arm.
• how: Background Pegloticase is approved in the the authors for treatment of Since disease (CKD) is common in these patients the authors conducted post-hoc analysis . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.